Review of macrophage phenotypes (M1, M2, etc) in rheumatic diseases. In RA synovial Tiss macrophages - are MerTK+CD206+

Tweet Author

Tweet Content

Review of macrophage phenotypes (M1, M2, etc) in rheumatic diseases. In RA synovial Tiss macrophages - are MerTK+CD206+ w/ remission and MerTK−CD206− w/ active inflammation. Tissue fibrosis in PSS driven by Profibrotic CD206+ and CD163+ cell subsets https://t.co/vIG7SYsaWq https://t.co/OKnzOFIlKr

Links

Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases https://buff.ly/EakgkZP

Pipeline of drugs being developed for Scleroderma by these companies - Bayer, Novartis, GSK, Boehringer Ingelheim, Celge

Tweet Author

RheumNow

Tweet Content

Pipeline of drugs being developed for Scleroderma by these companies - Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson, Prometic, Cytori arGentis - either as fusion proteins, peptides, small molecule, mAb, Polymern& Gene therapy https://t.co/dWRcQ1a3GU

5 August 2025

Juvenile Idiopathic Arthritis - NEJM Review

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

JIA is the most common form of inflammatory arthritis in the pediatric population and includes well characterized subtypes: oligoarticular JIA, polyarticular JIA, systemic JIA, psoriatic JIA, and enthesitis-related arthritis.

A New RA Approval (8.1.2025) Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA h

Tweet Author

RheumNow

Tweet Content

A New RA Approval (8.1.2025) Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA https://t.co/hHNvdOKp2z https://t.co/lUAZM7bY7X

Links

A New RA Approval (8.1.2025) | RheumNow https://buff.ly/Y14IvYi

RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkd

Tweet Author

RheumNow

Tweet Content

RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkdUQclz a. just getting started… b. More research &scholarship c. Growing a successful practice d. Greater knowledge and expertise e. Closer to burn-out

Links

Changing Rheumatology Practice & Choices | RheumNow https://rheumnow.com/survey/changing-rheumatology-practice-choices

UL nerves. https://t.co/CvqjMC0p0o

Tweet Author

MoAImam

Tweet Content

UL nerves. https://t.co/CvqjMC0p0o

Links

https://x.com/MoAImam/status/1951533433865331174/photo/1

Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significa

Tweet Author

ACR_Journals

Tweet Content

Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significant differences across sJIA clinical phenotypes, with dynamic changes linked to treatment response over time ACR Open Rheumatology https://t.co/GU5y70EXiI https://t.co/oCiKd0INuT

Links

Associations of Lymphocyte Subpopulations, Related Cytokines, Clinical Phenotyp… https://doi.org/10.1002/acr2.70070

https://x.com/ACR_Journals/status/1952469616761983281/photo/1

🧵 Vasculitis is Not One Disease – It’s a Spectrum It’s not a diagnosis. It’s a mechanism. From small-vessel p

Tweet Author

Rheumat_Aravind

Tweet Content

🧵 Vasculitis is Not One Disease – It’s a Spectrum It’s not a diagnosis. It’s a mechanism. From small-vessel purpura to large-vessel aneurysms, here’s how to recognize and reason through the vasculitis spectrum👇 @Amansharmapgi @DurgaPrasannaM1 @12VRavindran @Kanjivellam https://t.co/eEalTpDTGD

Links

https://x.com/Rheumat_Aravind/status/1952784364452102250/photo/1

Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentiall

Tweet Author

RheumNow

Tweet Content

Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentially beneficial are sulfasalazine, hydroxychloroquine, & leflunomide. More info needed on IL-6, IL-17/23 inhibitors. Concerns over NSAIDs & JAKi https://t.co/INEdCt0pxa

Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of

Tweet Author

RheumNow

Tweet Content

Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of de novo heart failure (HF), and no significant risk of HF worsening w/ TNFis. https://t.co/9sRVsMZ1kv https://t.co/Kapg9ZwVGf

Links

Journal of the European Academy of Dermatology and Venereology | Wiley Online L… https://buff.ly/hlbeneY

Topics

Review of macrophage phenotypes (M1, M2, etc) in rheumatic diseases. In RA synovial Tiss macrophages - are MerTK+CD206+

Pipeline of drugs being developed for Scleroderma by these companies - Bayer, Novartis, GSK, Boehringer Ingelheim, Celge

A New RA Approval (8.1.2025) Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA h

RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkd

UL nerves. https://t.co/CvqjMC0p0o

Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significa

🧵 Vasculitis is Not One Disease – It’s a Spectrum It’s not a diagnosis. It’s a mechanism. From small-vessel p

Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentiall

Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of

Do you get our email newsletter?